Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

NRF2 transcriptionally activates DDIT4 to drive venetoclax resistance in AML

Shuyun Cao, JiShi Wang Nov 03, 2025 pp. 6820-6820 10.1182/blood-2025-6820

Abstract Background: Relapse and refractory disease remain major challenges in acute myeloid leukemia (AML), with venetoclax resistance sign...

Multicenter evaluation of guideline adherence for the timeliness of pain medication for acute sickle cell disease pain

Ibrahim Gwarzo, Harish chandra Dega, David Brousseau Nov 03, 2025 pp. 121-121 10.1182/blood-2025-121

Abstract Background Recurrent pain episodes are the leading cause of emergency department (ED) visits among patients wit...

Erythroid-specific, inducible CDAN1∆/∆ mouse model phenocopies congenital dyserythropoietic anemia type-la

Corbin Azucenas, Aikaterini Voulgaridou, Yasmin Elgammal et al. Nov 03, 2025 pp. 186-186 10.1182/blood-2025-186

Abstract Congenital dyserythropoietic anemias (CDAs) are a heterogenous group of inherited blood diseases, characterized by ineffective eryt...

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito et al. Nov 03, 2025 pp. 5792-5792 10.1182/blood-2025-5792

Abstract Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized the tr...

ELN milestone-driven TKI switching improves deep molecular response rates in chronic myeloid leukemia

Lisi Huang, Chengxin Deng, Zesheng Lu et al. Nov 03, 2025 pp. 5563-5563 10.1182/blood-2025-5563

Abstract Background: Deep molecular response (DMR) is a prerequisite for successful treatment-free remission (TFR) in patients with chronic...

Sickle cell disease survival analysis at a large United States southern comprehensive sickle cell disease center: 1995 - 2022

Melinda Chance, Jeffrey Lebensburger, Kristen Osborn et al. Nov 03, 2025 pp. 6225-6225 10.1182/blood-2025-6225

Abstract Background: The University of Alabama at Birmingham (UAB) sickle cell disease (SCD) comprehensive center cares for most patients wi...

Artificial intelligence (AI) meets real-world disparities: A SEER-based study of Acute Myeloid Leukemia (AML) across race, ethnicity and gender

Jahnavi Ethakota, Venumadhavi Gogineni, Haseeb Tareen et al. Nov 03, 2025 pp. 6413-6413 10.1182/blood-2025-6413

Abstract Background - As artificial intelligence (AI) is increasingly being integrated into hematology, concerns about fairness and equitabl...

CD90-targeted multiplex virus-like particles (MVPs) for concomitant In Vivo gene editing, transduction, and transcription factor delivery into HSCs

Justin Thomas, Stefan Radtke, Dnyanada Pande et al. Nov 03, 2025 pp. 2543-2543 10.1182/blood-2025-2543

Abstract In vivo delivery strategies will substantially broaden the accessibility of Hematopoietic Stem Cell (HSC) gene therapy. However, cu...

Improved survival outcomes in angioimmunoblastic T-cell lymphoma linked to care at academic cancer centers: A national cancer database study.

Vanessa Velazquez, Leyla Bojanini, Erin Kaser et al. Nov 03, 2025 pp. 2763-2763 10.1182/blood-2025-2763

Abstract Intro Angioimmunoblastic T cell lymphoma is a unique subtype of peripheral T cell lymphoma (PTCL), often associated with poor progn...

MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis

Tal Zvida-Bloch, Eli Muchtar, Ifat Abramovich et al. Nov 03, 2025 pp. 5709-5709 10.1182/blood-2025-5709

Abstract Introduction Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by the deposition of misfolded im...

Evaluation of STAT6 and PD-L1 expression in Hodgkin/reed-sternberg (HRS)-like cells in Hodgkin lymphoma-like Richter transformation arising in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Yong Zhang, Yin Hung, Geraldine Pinkus et al. Nov 03, 2025 pp. 5407-5407 10.1182/blood-2025-5407

Abstract Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with classical Hodgkin lymphoma like Richter transformation (cHL-...

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

Wei Liu, Yan Xu, Yi Wang et al. Nov 03, 2025 pp. 3720-3720 10.1182/blood-2025-3720

Abstract Background Three CD19-directed CAR T-cell therapies - axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and ti...

Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia

Harshita Ravi, Qian Wang Nov 03, 2025 pp. 6764-6764 10.1182/blood-2025-6764

Abstract Introduction: Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by the clonal expansion of undiffe...

Multi-omic analysis of early minimal residual disease identifies functional and transcriptomic signatures of treatment resistance in pediatric B-cell acute lymphoblastic leukemia

Riccardo Scribano, Adrian Delgado, Pablo Domizi et al. Nov 03, 2025 pp. 334-334 10.1182/blood-2025-334

Abstract Background Relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL) remains a leading cause of cancer-related death...

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan et al. Nov 03, 2025 pp. 3865-3865 10.1182/blood-2025-3865

Abstract Introduction: Marrow complete remission (mCR) in 2006 IWG criteria for MDS (Cheson B et al, Blood 2006) reflects achieving bone marr...

Impact of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) on kidney functions in allogeneic stem cell transplant patients receiving tacrolimus

Saad Javaid, Jennifer Collins, Amir Kamran Nov 03, 2025 pp. 2503-2503 10.1182/blood-2025-2503

Abstract Background Tacrolimus is a cornerstone for graft-versus-host disease prophylaxis (GVHD) after allogeneic hemato...

MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial

Florent Malard, Jaime Sanz, Clemence Mediavilla et al. Nov 03, 2025 pp. 817-817 10.1182/blood-2025-817

Abstract Introduction Refractory acute graft-versus-host disease (aGvHD) is a significant cause of mortality following allogeneic hematopoie...

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Tapan Kadia, Caitlin Rausch, Gheath Alatrash et al. Nov 03, 2025 pp. 1646-1646 10.1182/blood-2025-1646

Abstract Background: Allogeneic (allo) stem cell transplantation (SCT) has been associated with improvement in long term outcomes in patient...

SNAI2 orchestrates a hypo-oxidative mitochondrial phenotype with elevated FAO dependence in acute myeloid leukemia

Xuntao Lai, Donghua Zhang, Longlong Liu et al. Nov 03, 2025 pp. 3477-3477 10.1182/blood-2025-3477

Abstract Introduction Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor long-term survival despite intensive therapeutic r...

Secondary HLH: A complication of anaplasmosis infection

Marina Khan, Faisal Shariff, Emeka Agudile et al. Nov 03, 2025 pp. 6564-6564 10.1182/blood-2025-6564

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is an inflammatory condition. More specifically, there is an improper cytoto...

Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed/refractory multiple myeloma

Malin Hultcrantz, Hani Hassoun, Neha Korde et al. Nov 03, 2025 pp. 4060-4060 10.1182/blood-2025-4060

Abstract Background B-cell maturation antigen (BCMA) directed therapies have demonstrated high efficacy in multiple myeloma (MM). While BCMA...

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Paola Ghione, Roni Shouval, Rita Tavarozzi et al. Nov 03, 2025 pp. 5341-5341 10.1182/blood-2025-5341

Abstract Introduction: In lymphoma, a non-disrupted gut microbiome has been associated with clinical response to CD19 CAR T (Smith et al., N...

Real-world outcomes of PK/PD-guided individualized emicizumab dose reduction in Chinese pediatric patients with hemophilia A: A prospective observational study

Qianqian Mao, Zhengping Li, Zhenping Chen et al. Nov 03, 2025 pp. 4840-4840 10.1182/blood-2025-4840

Abstract Background Emicizumab has markedly improved bleed prevention in hemophilia A, but its high cost remains a challenge, especially in...

A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies

Brandon Aubrey, Peter Miller, Timothy Graubert et al. Nov 03, 2025 pp. 2086-2086 10.1182/blood-2025-2086

Abstract Background: Myelodysplastic syndrome (MDS) is risk-stratified according to cytopenias, bone marrow blast percentage, and chromosoma...

Evaluating the impact of language on health care utilization outcomes in paitents with diffuse large B-cell lymphoma at a large safety-net hospital

Sarika Gurnani, Grace Ferri, Alyssa Quinn et al. Nov 03, 2025 pp. 2640-2640 10.1182/blood-2025-2640

Abstract Introduction: In the United States 25 million people have limited English proficiency. Individuals with limited English proficiency...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page